CG Oncology
CG Oncology's revenue rose 254.7% to $4 million in fiscal 2025. Its operating margin was −4,722.1%, up from −10,067.2% a year earlier. Free cash flow was −$132 million. The diluted share count rose 23.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What CG Oncology does
CG Oncology is a late-stage clinical biopharmaceutical company, which means it is testing a medicine in large trials and has no approved product yet. It has one product candidate, cretostimogene grenadenorepvec, a treatment made from a virus that is designed to kill cancer cells directly and to prompt the immune system to attack the tumor.
The target is bladder cancer that has not yet grown into the muscle wall (non-muscle invasive bladder cancer). Its main Phase 3 trial, BOND-003 Cohort C, covers high-risk patients whose cancer did not respond to the standard BCG treatment. For these patients, the next step is usually removal of the whole bladder. CG Oncology began submitting an application to the U.S. Food and Drug Administration in late 2025 and expects to finish it in 2026. A second Phase 3 trial, PIVOT-006, tests the treatment in intermediate-risk patients after tumor removal.
It relies on a partner, Biovire, and other third parties to make the drug and to run its trials.
Its biggest risks, as it describes them
- It depends entirely on cretostimogene, its only product candidate.
- Its approach to treating cancer is new, so the time and cost of development and approval are hard to predict.
- Trial results may be unfavorable, or the drug may cause side effects that delay or block approval.
- It relies on third parties, including Biovire, to run trials and make and ship the drug.
Income statement
CG Oncology lost money in fiscal 2025: a net loss of $161 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 188 | 742 | 742 |
| Debt incl. finance leases | — | 0 | 3 |
| Net debt (negative means net cash) | — | −742 | −739 |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | 0.0x | 0.0x |
| Interest coverage | −147.5x | — | −1,852.2x |
| Current ratio | 13.6x | 35.3x | 24.6x |
| Quick ratio | 13.6x | 35.3x | 24.6x |
Cash flow
Projections
Project CG Oncology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What CG Oncology says to expect
- Cash position: funding of operations
The Company anticipates its existing cash, cash equivalents and marketable securities as of this date will be sufficient to fund operations through 2029.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $24.8 million of CG Oncology shares on the open market, and 2 insiders sold $4.8 million, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Leonard E PostDirector | Sold plan | 1,000 | $72.98 | $72,980 | Form 4 |
| Aug 14, 2026 | Leonard E PostDirector | Sold plan | 1,000 | $74.54 | $74,540 | Form 4 |
| Jul 15, 2026 | Leonard E PostDirector | Sold plan | 1,000 | $71.17 | $71,170 | Form 4 |
| Jul 10, 2026 | James MulayDirector | Sold plan | 24,165 | $75.16 | $1.8 million | Form 4 |
| Jun 25, 2026 | Brian Guan-Chyun LiuDirector | Bought plan | 371,085 | $66.87 | $24.8 million | Form 4 |
| Jun 24, 2026 | Leonard E PostDirector | Sold plan | 5,000 | $70.00 | $350,000 | Form 4 |
| Jun 22, 2026 | Leonard E PostDirector | Sold plan | 5,000 | $65.00 | $325,000 | Form 4 |
| Jun 15, 2026 | James MulayDirector | Sold plan | 1,964 | $60.12 | $118,076 | Form 4 |
| Jun 4, 2026 | Leonard E PostDirector | Sold plan | 1,000 | $54.50 | $54,500 | Form 4 |
| Apr 17, 2026 | James MulayDirector | Sold plan | 15,600 | $73.01 | $1.1 million | Form 4 |
| Mar 16, 2026 | James MulayDirector | Sold plan | 1,964 | $63.50 | $124,714 | Form 4 |
| Jan 9, 2026 | James MulayDirector | Sold plan | 11,145 | $52.47 | $584,799 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | 2 of 8 |
| Rule of 40 | −6,472.9% | −3,024.5% |
| Altman Z'' | 40.36 | 23.13 |
| Accruals ratio | −1.9% | −3.7% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Pass |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | Fail |
| Current ratio rose | Pass | Fail |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | Fail |
| F-score | — | 2 of 8 |
Compare
Put CG Oncology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| CG Oncology | FY25 | 254.7% | −4,722.1% | −3,279.2% | — | — | 2 | |
| CRISPR Therapeutics | FY25 | −90.6% | −18,933.7% | −9,855.5% | — | — | — | Compare |
| Prime Medicine | FY25 | 55.3% | −4,498.1% | −3,607.4% | — | — | — | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
| Roivant Sciences | FY25 | −71.6% | −6,235.7% | −9,183.5% | −62.6% | — | 1 | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 0 | 1 | 4 |
| Revenue growth | — | 458.3% | 254.7% |
| Gross profit | — | — | — |
| Research and development | 46 | 82 | 117 |
| Operating income | −55 | −115 | −191 |
| Net income | −49 | −88 | −161 |
| Diluted EPS (US$) | −15.65 | −1.41 | −2.08 |
| Diluted shares (millions) | 4 | 62 | 77 |
| Cash flow | |||
| Cash from operations | −46 | −79 | −132 |
| Capital expenditure | — | 0 | 0 |
| Free cash flow | — | −79 | −132 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 22 |
| Stock-based compensation | 2 | 11 | 27 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 188 | 742 | 742 |
| Debt incl. finance leases | — | 0 | 3 |
| Total assets | 199 | 755 | 792 |
| Total liabilities | 14 | 21 | 39 |
| Shareholders' equity | −123 | 733 | 753 |
| Margins and ratios | |||
| Gross margin | — | — | — |
| Operating margin | −27,180.9% | −10,067.2% | −4,722.1% |
| Net margin | −23,827.0% | −7,729.5% | −3,985.0% |
| Free cash flow margin | — | −6,931.3% | −3,279.2% |
| Rule of 40 (growth + FCF margin) | — | −6,472.9% | −3,024.5% |
| Return on capital | — | — | — |
| Return on equity | — | −28.9% | −21.7% |
| Return on assets | — | −18.4% | −20.8% |
| Net debt to EBITDA | — | — | — |